The Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs.

The prices go into effect in 2027, including a monthly price of $274 for Novo Nordisk’s popular GLP-1 drug semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes.

Medicare’s recent net price for Ozempic was $428 a month, according to an analysis published in the Journal of Managed Care and Specialty Pharmacy. Medicare put the drug’s list price, before confidential rebates and discounts, at $959 a month.

Based on such nondiscounted list prices, Medicare said savings on the 15 drugs ranged from 38% to 85%.

“They were gonna go to the table and try a

See Full Page